LEXICON PHARMACEUTICALS, INC. Property, Plant and Equipment, Gross
LEXICON PHARMACEUTICALS, INC. (LXRX) had Property, Plant and Equipment, Gross of $4.57 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-08-06
- 2026-06-30: Property, Plant and Equipment, Gross $4.57M.
- 2026-03-31: Property, Plant and Equipment, Gross $4.57M.
- 2025-12-31: Property, Plant and Equipment, Gross $4.57M.
- 2025-09-30: Property, Plant and Equipment, Gross $4.57M.
| Period end | Property, Plant and Equipment, Gross |
|---|---|
| 2026-06-30 | $4.57M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.57M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.57M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $4.57M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.57M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $4.57M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $4.57M 10-K · filed 2026-03-05 |
| 2024-09-30 | $4.10M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.79M 10-Q · filed 2024-08-02 |
| 2023-12-31 | $6.53M 10-K · filed 2025-03-07 |
| 2022-12-31 | $6.05M 10-K · filed 2024-03-25 |
| 2021-12-31 | $6.03M 10-K · filed 2023-03-03 |
| 2021-09-30 | $6.16M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $5.95M 10-Q · filed 2021-08-06 |
| 2020-12-31 | $6.11M 10-K · filed 2022-03-10 |
| 2019-12-31 | $75.79M 10-K · filed 2021-03-12 |
| 2018-12-31 | $75.87M 10-K · filed 2020-03-12 |
| 2017-12-31 | $76.31M 10-K · filed 2019-03-15 |
| 2016-12-31 | $79.27M 10-K · filed 2018-03-01 |
| 2015-12-31 | $80.66M 10-K · filed 2017-03-06 |
| 2014-12-31 | $37.35M 10-K · filed 2016-03-11 |
| 2013-12-31 | $123.31M 10-K · filed 2015-03-12 |
| 2012-12-31 | $126.05M 10-K · filed 2014-03-07 |
| 2011-12-31 | $126.95M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |